Skip to main
ALZN

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc has demonstrated positive momentum in its clinical development, evidenced by the favorable top-line results reported in June 2023, which support the viability of its therapeutic candidates aimed at treating neurodegenerative diseases. The company's attractive current valuation indicates substantial potential upside based on a net present value (NPV) analysis, enhancing investor interest. Additionally, the progress towards achieving key milestones and the generation of positive data are expected to serve as significant catalysts for the company's stock performance moving forward.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share of $(1.28), which was significantly worse than prior estimates of $(0.69). The company faces substantial risks, including potential failures of its drug candidates to demonstrate safety and efficacy in clinical trials, challenges in gaining regulatory approvals, and difficulties in commercialization and reimbursement. Moreover, the overall environment for biotech investments, alongside balance sheet and liquidity risks, further compounds the negative outlook for Alzamend Neuro's stock.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.